Canada markets closed

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.6200-0.0400 (-1.50%)
At close: 03:59PM EST
Sign in to post a message.
  • C
    Charlie
    The January 14 2022 NervGEN webcast---Focus is on Spinal Cord Injury

    NervGEN Unleashing the Nervous System to Repair and  Heal Itself- including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).

    https://biopub-webcasts.s3.amazonaws.com/January+14%2C+2022%3A+NervGen's+Fresh+Take+on+the+Silver+Cord
  • J
    John
    Yesterday, we announced our plan to initiate our clinical trial for spinal cord injury (SCI) patients later this year. I would like to focus your attention on three highlights:

    we are including a “chronic” group of patients in this trial,
    we have strategically chosen to run a single site trial, and
    we are running our trial at Shirley Ryan AbilityLab in Chicago, voted the “No. 1 Rehabilitation Hospital in America” by U.S. News & World Report every year since 1991.

    Most clinical trials for drugs to treat spinal cord injuries target those with “acute” injuries, meaning they administer the drug to patients that suffered their injuries within hours or days. It is rare that a clinical trial includes a patient group that suffered their injury one year previously. We are enthused and justified to include a patient group that is ≥1-year post-injury based on the preclinical evidence we have collected. If we are able to achieve a meaningful level of functional improvement in this “chronic” group, this would be the first clinical evidence to give hope to the hundreds of thousands of people that have been suffering from a spinal cord injury for a long period of time.

    While there are several excellent, leading edge spinal cord injury treatment and rehabilitation facilities, Shirley Ryan AbilityLab’s combination of world-renowned expertise in the management of SCI patients, vast experience in monitoring recovery in SCI patients using sophisticated electrophysiology techniques and the large number of SCI patients that seek care at their facilities moved the hospital to the top of the list for this trial. And by restricting our trial to one center, we can include more sophisticated variables in our analyses that we would not be able to include in a multi-center trial.

    We are very confident that this very important relationship with Shirley Ryan AbilityLab will result in the most effective and expeditious clinical trial possible.

    About Shirley Ryan AbilityLab
    It is the global leader in physical medicine and rehabilitation for adults and children with the most severe, complex conditions – from traumatic brain and spinal cord injury to stroke, amputation and cancer-related impairment. The Shirley Ryan AbilityLab expands and accelerates leadership in the field that began at Rehabilitation Institute of Chicago in 1953 – its care and research designated it the “No. 1 Rehabilitation Hospital in America” by U.S. News & World Report every year since 1991. Upon opening in March 2017, the $550 million, 1.2 million square foot Shirley Ryan AbilityLab became the first-ever “translational” research hospital where clinicians, scientists, innovators and technologists work together in the same space, surrounding patients, discovering new approaches and applying (or “translating”) research in real time.

    I trust you will find this news release as compelling and important as we do. To learn more about our spinal cord injury program, click here.If you have any comments or questions, please do not hesitate to reach out to us directly.

    Sincerely,
    Paul Brennan
    President & CEO
  • J
    John
    January 12, 2021  Unleashing the Nervous System to Repair and  Heal Itself- including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).

    NervGen Pharma Zoom Presentation

    https://www.youtube.com/watch?v=0hMIwSSVWLM
  • J
    John
    NervGen Pharma (TSX-V: NGEN & OTC: NGENF) Zoom Presentation - January 20, 2022

    Focus on 42 minutes to 56 minutes for new updates

    https://www.youtube.com/watch?v=fam_qqUhVkE&t=128s
    NervGen Pharma (TSX-V: NGEN & OTC: NGENF) Zoom Presentation - January 20, 2022
    www.youtube.com
  • C
    Charlie
    BioPub and San Diego Torrey Hills Capital invite you to a Zoom webinar

    Date: Friday, 14 January 2022 Time: Noon ET
    NervGen's Fresh Take on the Silver Cord
    Later taken as metaphor for the spinal cord, in ancient literature, the silver cord connects higher and astral forms of the self with the earthly body. NervGen's scientific founder Dr Jerry Silver's earliest work pertained to spinal cord injury, and rejiggering topical biochemistry to enable neural regeneration. While cord injury was in the earliest purview of NervGen, the company also embraced a genuine latent pipeline of uses for the lead agent created by Silver, including MS, AD, CVA and TBI. In NervGen comes full circle back to its origins in spinal cord injury focus, with the help of leading edge neurology collaborator Dr. James Guest.

    Featuring

    Special Guest James Guest, MD, University of Miami
    NervGen CEO Paul Brennan
    NervGen CMO Dan Mikol, MD, PhD
    NervGen Co-Founder Harold Punnett, DMD

    Host

    Mark Swaim, MD, PhD
    Jonathan Coulborn

    General audience access:

    Please click the link below to join the webinar:
    https://us02web.zoom.us/j/84137462982

    Or One tap mobile :
    US: +13017158592,,84137462982# or +13126266799,,84137462982#
    Or Telephone:
    Dial(for higher quality, dial a number based on your current location):
    US: +1 301 715 8592 or +1 312 626 6799 or +1 646 558 8656 or +1 253 215 8782 or +1 346 248 7799 or +1 669 900 9128
    Webinar ID: 841 3746 2982
    International numbers available: https://us02web.zoom.us/u/kpra7J0hp
    Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference ro
    Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference ro
    us02web.zoom.us
  • M
    Mark
    What's going on? Why the sudden drop?
  • C
    Charlie
    NervGen aiming NVG-291 at treating spinal cord injury, multiple sclerosis and Alzheimer’s disease.

    Earlier this month, the company reported preliminary data from an ongoing Phase 1 trial, with iA Capital Markets analyst Chelsea Stellick reporting that the results show an excellent trajectory in the study’s first 25 subjects.

    “The pharmacokinetic data from cohorts one through four show a more favourable profile in humans than in rodents, including a longer half-life (detectable up to 12 hours post-dose) alongside rapid distribution in the blood. These signals are very encouraging since this means NVG-291 is likely to have an even stronger effect in humans than it had in rodents, all else equal. Given the profound efficacy already seen in rodents, these early signals exceeded our expectations and are very promising for the prospect of bringing NVG-291 to humans,” Stellick wrote in an October 18 update.
  • C
    Charlie
    Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed NervGEN CEO Paul Brennan..

    https://soundcloud.com/user-759550640/paul-brennan-recent-advances-in-creating-new-neural-pathways-for-spinal-cord-injury?
  • J
    John
    NervGen (NGENF): New Alzheimer drug could have ‘blockbuster potential

     Are there any other developments on the horizon that you can tell us about? 

    • Presenting preclinical data in stroke, chronic spinal cord injury and Alzheimer's disease models; all of which could represent completely new treatment paradigms 

    • Updates on the progress of the multiple ascending (MAD) portion of our ongoing Phase 1 study

     • Removal of the ongoing partial clinical hold, initiation of Phase 1 bridging studies and reporting of results on bridging studies

    • Initiation of Phase 1b/2 study in Alzheimer’s disease

     • Initiation of Phase 2 study in MS 

    • Initiation of Phase 1b/2 study in spinal cord injury 

    • Awarding of non-dilutive grants to support our research activities, which if successful could come from the US DoD [Department of Defense] or from private sources.

    "Our platform technology has the potential to restore the function and therapeutic outcomes for all central nervous system damage, including multiple sclerosis, Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury,” Paul Brennan, president and CEO of NervGen.

    Amazing Efficacy in animals during trials.

    NervGEN NGENF Elevator Summary Here

    https://wp.me/p33WjT-2
  • J
    John
    What makes NVG-291 different from other drugs in development in neurological disorders?

    Paul Brennan: There are multiple factors that differentiate NVG-291 from other drugs in development for neurological disorders.

    NVG-291’s mechanism of action works through repairing and restoring neurological function. Most other drugs in development in the CNS space are focused on slowing the progression of the disease, and most neurological diseases are very slowly progressing. With this differentiated approach, we should see a quicker response, and that response should be seen with fewer patients.

    Whereas most drugs in development have only one pharmacodynamic response, NVG-291 has a multi-modal mechanism of response (axon regeneration, increased plasticity, remyelination).

    The scope, pattern, and magnitude of response seen in functional studies with NVG-291 are broad and deep compared to other products in development. For example, firstly, NervGen believes it has the potential to be effective in any disorder where there is damage to the nervous system, whether acute or chronic. Secondly, NVG-291 demonstrates pharmacological activity across the major neurological functions (autonomic function, sensory function, cognition, and motor control). And thirdly, in some experiments, such as SCI, the magnitude of response seen with NVG-291 treatment has never been seen before.

    https://pharmashots.com/66471/pharmashots-interview-paul-brennan-shares-insights-on-nvg-291-and-its-interim-data-for-the-treatment-of-neurodegenerative-diseases/
  • D
    D
    NVG-291 will show better efficacy for conditions resulting from acute insult as opposed to chronic insult. It will be a very effective compliment therapy to SOC in MS and to some pipeline AD programs. NervGen should position clinical strategy accordingly. Without interdiction in the underlying disease pathology causing chronic insult, the benefit of neuro-regeneration will be offset/masked. If the clinical strategy does not include this thinking the stock price will be whipsawed as trial results are posted.
  • J
    John
    NervGEN Pharma ( NGENF ) is a public company. www.nervgen.com

    NervGEN is unleashing the Nervous System to Repair and Heal Itself-Focusing on multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI). NervGEN’s technology is applicable to all Nervous System Diseases.

    Based upon thirty years of research by Dr. Jerry Silvers Case University and Cleveland Clinic


    PHD left AMGEN to become Chief Medical Officer of NervGEN Dr Dan Mikol. Reason: Dr Silvers 30 years of research

    Founding and current Editor of Journal of Alzheimer’s Disease Dr George Perry is on the NervGEN Advisory Board

    Dr George Perry has stated: "If you have a drug that actually changes the biology of the disease (i.e. NervGEN's NVG -291) why do you need 100's to see (in clinical trial)? .......NervGEN's NVG-291 "may change the course of the disease...maybe not full recovery..... "I am actually quite enthusiastic."

    NervGEN likely to receive nondilutive financing from the Department of Defense for Traumatic Brain Injury (TBI) Research

    Dr Michael Davis- (Retired Colonel) --Traumatic Brain Injury and the Department of Defense "The mechanism of this (NervGEN peptide NVG-291) is unique....it's had significant preclinical validation in the central nervous system....... I feel very strongly that this has high likely chance of success"

    ‘Proven functional recovery demonstrated in 6 different disease models with benefits crossing multiple neurological functions’

    NervGEN is developing a revolutionary new class of drugs that REPAIRS damage to the Nervous System and restores motor sensory and cognitive function. Currently there are no approved "neurorestorative" drugs.

    Delivered systemically via injection, NervGen's drug (NVG-291) REPAIRS the nervous system at the site of damage with a mechanism of action that results in multiple modes of repair-including regeneration, remyelination and enhanced plasticity.

    NervGEN's published results from animal models of damage and disease are unprecedented both in scope and magnitude of effect, including spinal cord injury, multiple sclerosis (MS), stroke, cardiac arrythmia and peripheral nerve injury.

    Backed by three decades of scientific research by Dr. Jerry Silvers, NervGEN's platform technology has the potential to redefine therapeutic outcomes for ALL central nervous system damage-including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).

    NervGEN's lead product, NVG-291, is the only drug of its kind in clinical development. Most nervous system drugs in development are aimed at stopping or SLOWING the progressive of the disease not REPAIRING. No treatment exists that "rewires" the damaged nerve connections and results in improvement.

    NervGEN is hoping for Breakthrough Status from FDA on 3 fronts: Alzheimer’s Disease, MS and Spinal Cord Injury

    In 2003 Dr Jerry Silvers was honored with the Christopher Reeve-Joan Irvine Research Medal (The Reeve-Irvine Medal) for critical contributions that may lead to the promotion of repair of the damaged spinal cord.

    NervGen Pharma Zoom Presentation

    See Mice Given NervGEN Drug NVG-291 - A MIRACLE
    9:24 Spinal Cord Injury
    41:02 Spinal Cord Injury
    55.18 MS Multiple Sclerosis

    https://www.youtube.com/watch?v=INWe40Kb8gQ

    Paradigm Capital NervGEN Analyst Report 10/13/21

    https://biopub-wordpress-media.s3.amazonaws.com/wp-content/uploads/2021/10/14170153/ngen-2021-10-13_Initiating-Coverage.pdf

    Encode initiation report on NervGEN September 13, 2021

    https://www.encodelp.com/wp-content/uploads/EI-NGEN-Report.pdf

    Revolutionary drug ‘could reverse damage’ caused by Alzheimer’s by allowing nerve cells to mend themselves, scientists say

    https://www.tech-gate.org/usa/2021/10/03/revolutionary-drug-could-reverse-damage-caused-by-alzheimers/

    Dr Jerry Silvers
    https://www.youtube.com/watch?v=NGWhkDI7woI



    NervGen's Alzheimer's Disease Clinical Advisory Board

    Jeffrey Cummings, MD, ScD
    Martin Farlow, MD
    Bruce Lamb, PhD
    George Perry, PhD ( Founding and Current Editor-in-Chief Journal of Alzheimer's Disease)
    Reisa Sperling, MD
    Michael Weiner, MD (Published over 903 peer-reviewed articles)
    Henrik Zetterberg, MD, PhD



    NervGEN’s Multiple Sclerosis Clinical Advisory Board

    Jack Antel, MD
    Peter Calabresi, MD
    Jeremy Chataway, MD
    Jeffrey Cohen, MD
    Robert Naismith, MD
    Anneke van der Walt, MD, PhD


    Spinal Cord Injury Clinical Advisory Board

    James Guest, MD, PhD, FACS
    Steven Kirshblum, MD
    Brian Kwon, MD, PhD, FRCSC
    Linda Jones, PT, PhD
    Linda Jones, PT, PhD
    Restoring Life’s Potential with Innovative Solutions for the Treatment of Nerve Damage About NervGen NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing treatments for patien
    Restoring Life’s Potential with Innovative Solutions for the Treatment of Nerve Damage About NervGen NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing treatments for patien
    www.nervgen.com
  • C
    Charlie
    Dr. Jerry Silver **Case Western Reserve University School of Medicine - 10/12/21 4:46

    The molecule behind NervGEN Pharma

     https://www.youtube.com/watch?v=NGWhkDI7woI
    Case Western Reserve University School of Medicine - (CAHH) The Council to Advance Human Health
    www.youtube.com
  • C
    Charlie
    U.S. Senate Defense Bill Includes NervGEN Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury

    https://finance.yahoo.com/news/u-senate-defense-bill-includes-123000793.html

    September 9, 2021  NervGEN Annual Meeting

    Explained here by Dr. Michael Davis (Retired Colonel) Non-Dilutive funding for NervGEN-$NGENF-From the Department of Defense---at  34:50-46:50 mark in the video

    Dr. Michael R Davis 34:50 to 46:50  At 45:26 "I feel very strongly that this has high likely chance of success"

    Video

    https://www.youtube.com/watch?v=rkcHYZn4-5Y&t=2452s
  • J
    John
    August 12, 2021 Unleashing the Nervous System to Heal Itself 

    8 minutes 53 seonds to 9:18 CEO Paul Brennan  talks about NervGEN technology being applicable to ALL Central Nervous System Diseases  

    26:20 NervGEN NVG-291 34:20 Slide 14 Neurodegenerative diseases Parkinson's NVG-291 has the potential to treat ALL CENTRAL NERVOUS DISEASES 

    See Mice Given NervGEN Drug NVG-291 

    9:24  Spinal Cord Injury

    41:02 Spinal Cord Injury55.18  MS  

    NervGEN Pharma Zoom Presentation

      https://www.youtube.com/watch?v=INWe40Kb8gQ
    NervGen Pharma Zoom Presentation - August 12, 2021
    www.youtube.com
  • J
    John
    CMO NervGEN Dan Mikol on Spinal Cord Injury 

    Chief Medical Officer Dan Mikol

    "I actually feel the results of spinal cord injury are especially exciting because spinal cord injury is not a disease it is consequence of trauma and if you can show repair in this condition where there is damage to the nervous system why shouldn't this approach work in the other central nervous diseases like MS and Alzheimer's...."

    NervGEN conference

    https://biopub-webcasts.s3.amazonaws.com/October+20,+2021-+NervGen:+A+Key+Update+on+New+Phase+1+Data
  • x
    x
    Yahoo Finance list average vol for NGENF as 30,000 and the days vol ended up over 500K. I wonder who sold? The stock was halted before they announced the closing of the bought deal which was set below the market price.

    The problem with this stock is the volume.
  • D
    D
    Another point of conversation; do the CSPGs slow or impair further damage to nerve function caused by disease and would alleviation of the glial scarring allow acceleration of that damage coincidental with repair?
  • x
    x
    I told you that they will price the offering below the current market price and with low volume its easy to get in, but hard to get out in one piece.
  • L
    Lost it
    Good movement here. Slow buying says someone is excited.